- SCOVELLA® was developed to reduce hyperinsulinaemia in insulin-dysregulated horses, a key underlying driver of laminitis – a common, painful inflammatory condition in horses' hooves and significant unmet need in equine health.
- Laminitis is one of the most significant causes of pain and disability in horses, with one-third of affected horses euthanized within a year of diagnosis.1
- Once the European Commission follows the CVMP recommendation and grants a marketing authorization, SCOVELLA® would be the first therapy approved in the European Union for the reduction of hyperinsulinaemia and the reduction of associated risk of laminitis in horses with Equine Metabolic Syndrome.2
Ingelheim, Germany - Boehringer Ingelheim, a global leader in animal health, announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) has adopted a positive opinion for SCOVELLA® (velagliflozin oral solution), recommending marketing authorization in the European Union (EU).
“The CVMP's positive opinion for SCOVELLA® recognizes the significant need for new treatments for hyperinsulinaemia, a key underlying driver of laminitis in horses," said Saskia Kley, Global Head of Equine at Boehringer Ingelheim. “With this opinion, owners of horses with Equine Metabolic Syndrome in the EU are one step closer to a breakthrough innovation to reduce hyperinsulinaemia and reduce the associated risk of laminitis, one of the most devastating conditions in equine health.”
Equine Metabolic Syndrome is a collection of metabolic and clinical features that include insulin dysregulation (ID) as a core component, resulting in an increased risk of laminitis in horses.3
Laminitis is a common and painful inflammatory condition of horses' hooves and one of the most significant causes of pain and disability in horses, with one-third of affected horses euthanized within a year of diagnosis.1 Affecting an estimated one in five horses, insulin dysregulation is estimated to be associated with more than 90% of laminitis cases.4
Once SCOVELLA® is approved by the European Commission, it would be the first SGLT-2 inhibitor authorized for horses in the European Union. SCOVELLA® was approved and introduced in Great Britain earlier this year.
With 15 years of research behind SCOVELLA®, the SGLT-2 inhibitor is an example of Boehringer Ingelheim's commitment to advance equine health innovations in areas of high unmet need. The oral liquid medication is designed to inhibit glucose reabsorption in the kidneys, leading to a rapid and sustained reduction of insulin to address the main cause of laminitis.
About Boehringer Ingelheim – Animal Health business
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective. Our approximately 54,300 employees serve over 130 markets to build a healthier tomorrow. Learn more at www.boehringer-ingelheim.com.
References:
1 Luthersson, N., Mannfalk, M., Parkin, T. D., & Harris, P. (2017). Laminitis: risk factors and outcome in a group of Danish horses. Journal of Equine Veterinary Science, 53, 68-73.
2 Proposed indication: For the reduction of hyperinsulinaemia and reduction of associated risk of laminitis in horses with Equine Metabolic Syndrome not responsive to changes in husbandry and exercise regimen. See the CVMP summary of positive opinion.
3 Bertin, F. R., Bailey, S., Burns, T., De Laat, M., Durham, A. E., Frank, N., ... & Menzies-Gow, N. J. (2024). Recommendations for the diagnosis and management of equine metabolic syndrome (EMS) and insulin dysregulation. Equine Endocrinology Group.
4 Karikoski, N. P., Horn, I., McGowan, T. W., & McGowan, C. M. (2011). The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital. Domestic animal endocrinology, 41(3), 111-117.
-
资生堂第九届进博之旅圆满收官,签约第十届续写美丽未来“一瞬之美,一生之美”呈现多元美力,与中国共享创新机遇 上海2026年11月10日 美通社 -- 第九届中国国际进口博览会(以下简称“进博会”)今日圆满闭幕。连续八年参展的2026-11-10
-
勃林格殷格翰索弗度肽(survodutide)是首个在全球 III 期 SYNCHRONIZE-CVOT 试验中显示出良好心血管安全性的胰高血糖素GLP-1双受体激动剂,同时带来显著心血管代谢获益* SYNCHRONIZE-CVOT 试验达到主要终点。研究结果证实,在伴有已确诊心血管疾病(CVD)、慢性肾脏病,和或至少两项体重相关并发症或心血管疾病风险因素的肥胖人群中,索弗2026-11-10
-
TÜV莱茵与众擎机器人达成合作,助力众擎机器人加速全球化布局上海2026年11月9日 美通社 -- 11月7日,第九届中国国际进口博览会现场,国际独立第三方检测、检验和认证机构德国莱茵TÜV大中华区(以下简称“TÜV莱茵”)与深圳众擎机2026-11-10
-
诺和泰® 慢性肾脏病适应症获批专利权期限补偿,药品创新价值再获认可和保护北京2026年11月10日 美通社 -- 诺和诺德(以下简称“诺和”)今日宣布,旗下诺和泰® (司美格鲁肽注射液)慢性肾脏病(CKD)适应症相关专利的药品专利权期限补偿(Patent Term Ex2026-11-10
-
西岸中環四度联袂西岸艺博会:《Wonder Orbit環游奇境》特展启幕上海2026年11月10日 美通社 -- 西岸中環携手国际知名艺术家莫拉格 • 麦耶斯考夫(Morag Myerscough),于西岸中環标志性建筑西岸漩心(The Orbit)启幕其中国大陆首个室内2026-11-10
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
锚定健康中国新征程!第一届医药信息传播论坛将于广州启幕
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
